We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This statements provide some insight of the potential; if NHS signed up to use the test, huge revenue on the pipe line.
The antibody tests, which utilise the Quotient MosaiQ™ system and MosaiQ COVID-19 Antibody Microarray, offer best in class COVID-19 antibody testing performance and will require a full blood draw.
hVIVO COVID Clear Test will be offered to large employer groups and channel partners including GP networks, nursing services, health clinics and private hospitals. Samples will be tested in the Company's London laboratory with results returned within 48 hours.
On the contrary there is very minimal evidence of re-infection in the short term. Hence why antibody testing is absolutely critical particularly for the multinational businesses that CF is targeting. It’s not the only thing happening here, but it is a sure fire revenue stream in the absence of a vaccine
I agree SS17,
However, whilst I do highly rate the BoD and the product pf, I actually am not that enamoured by this call. I do not think antibody testing is a main event. Had they agreed to provide corporate antigen testing then I would see far more value.
CF “..."Antibody testing is crucial for guidance on immunity, ”....
Really, I haven’t seen any scientific evidence to substantiate this. On the contrary there is evidence of re-infection. This is riding a wave and the sooner they include or replace with antigen testing the better and more long term value will be realised.
Yes I’m still bullish but also try to be objective. Need to plug this gap quickly guys!
Trek
comments from
https://www.valuethemarkets.com/2020/05/18/open-orphan-share-price-spikes-as-covid-19-home-testing-stocks-rocket-orph/
"No other company in the world has a portfolio like Open Orphan. There are better-known companies, of course. But this company has advantages that no-one can reverse engineer. It is a world leader in human challenge studies and has Europe’s only 24-bed quarantine unit with a virology lab on-site.
Covid-19 aside, Open Orphan has major money-making deals already confirmed. It announced a £3.5 million contract signed earlier this month and a £3.2 million challenge study deal confirmed in March. It is also moving into Phase 3 clinical trials for the elusive and ground-breaking universal flu vaccine."